The Study of Exenatide Action on Vessel Function in Type 2 Diabetes and Prediabetes
Completed · Phase 4 · Has a placebo group
Conditions studied: Type 2 Diabetes Mellitus
In brief
The purpose of this investigation is to evaluate whether exenatide, a type 2 diabetes medication, will improve the function of the innermost part of the arterial wall called the endothelium after a fat-enriched meal and to determine how this occurs. The results of this study will help to determine and understand a novel action of this group of diabetes medications based on the action of naturally occuring gut substances called incretins. This may have a significant impact on cardiovascular health in patients with early and longstanding diabetes.
Key facts
- Study ID
- NCT01181986
- Run by
- Carl T. Hayden VA Medical Center
- People needed
- 76
- Starts
- 2010-08-01
- Expected to finish
- 2012-12-01
- Last updated by the study team
- 2014-05-20
Who can join
Age: 35 and older, up to 70. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- US Veterans
- type 2 diabetes mellitus (T2D) diagnosed within 3 years with good glycemic control on diet, metformin, or sulfonylurea agents or combinations of these agents (HbA1c ≤8.0%)
- T2D diagnosed ≥ 5 years prior to study enrollment
- Impaired glucose tolerance
You may not qualify if…
- T2D not meeting inclusion above criteria for duration of diabetes or HbA1c values
- known or suspected T1D (early onset age, low body mass index, lack of family history)
- TZD use in the prior 3 months
- prior regular use of insulin
- Creatinine >2.0 mg/dl or other laboratory or clinical evidence of kidney disease
- anemia
- known active liver disease or hepatic enzyme elevation two-and-a half times above normal
- acute bacterial or viral illness or evidence of other active infection in the past 4 weeks
- stable or unstable angina or other major illness in the past 6 months
- Raynaud's disease or any rheumatic disease affecting fingers
- current regular use of anti-inflammatory medications or antioxidants, including over the counter medications and high dose salicylates (>1 g/day);
- subjects receiving lipid lowering or anti-hypertension medications must be on stable doses for at least 2 months prior to participation.
Where it is running
- Phoenix VA Medical Center — Phoenix, Arizona, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.